SequelSEC

Perspective Therapeutics, Inc. CATX

Pharmaceutical Preparations · CIK 0000728387 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$2.53M
Fiscal year ended 2023-12-31
Operating income
-$40.94M
Fiscal year ended 2023-12-31
Free cash flow
-$37.98M
Fiscal year ended 2023-12-31

Valuation, from the filing

Public float$212.87MMarket value of stock held by non-affiliates, as stated on the cover page for 2025-06-30
Float per share$1.87Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today.

How this compares in its industry

Percentile among the Pharmaceutical Preparations filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
Gross margin100.0%97th
Current ratio1.07x17th

Perspective Therapeutics, Inc. (CATX) reported revenue of $2.53M and net income of -$46.51M for the fiscal year ended 2023-12-31. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from Perspective Therapeutics, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Perspective Therapeutics, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2023-12-31
Revenue$2.53M
Cost of revenueUnavailable
Gross profit$1.43M
Operating income-$40.94M
Net income-$46.51M
Research & development$21.31M
Weighted-average diluted sharesUnavailable
Pretax income-$40.11M
Income tax expense-$2.65M
Diluted EPSUnavailable
Selling, general & administrativeUnavailable
General & administrative$21.06M
Selling & marketingUnavailable

Balance

Perspective Therapeutics, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2023-12-31
Cash & equivalents$9.24M
Total assets$97.89M
Current assets$16.84M
Total liabilities$22.71M
Current liabilities$15.66M
Total equity incl. NCI$75.18M
Temporary (mezzanine) equityUnavailable
InventoryUnavailable
Accounts receivable$1.16M
Goodwill$24.06M
Long-term debt$1.72M
Accounts payableUnavailable

Cash flow

Perspective Therapeutics, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2023-12-31
Operating cash flow-$36.91M
Capital expenditures$1.07M
Investing cash flow$24.37M
Financing cash flow$785.00K
Net change in cash-$11.76M
Stock-based compensation$3.74M
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortization$1.01M

Derived

Perspective Therapeutics, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2023-12-31
Free cash flow-$37.98M
Gross margin56.7%
Operating margin-1617.6%
FCF margin-1500.8%
SBC / revenue147.7%
Current ratio1.07x
Revenue YoY growthUnavailable
Net margin-1837.5%
R&D / revenue842.0%
CapEx / revenue42.4%
Long-term debt / equity0.02x
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open CATX in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-10View SEC filing
10-Q · Filed 2026-05-11View SEC filing
10-K · Filed 2026-03-16View SEC filing
10-Q · Filed 2025-11-10View SEC filing
10-Q · Filed 2025-08-13View SEC filing
10-Q · Filed 2025-05-12View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.